摘要 |
<p>PCT No. PCT/EP97/02710 Sec. 371 Date Nov. 9, 1998 Sec. 102(e) Date Nov. 9, 1998 PCT Filed May 15, 1997 PCT Pub. No. WO97/44040 PCT Pub. Date Nov. 27, 1997This invention concerns the compounds of formula the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Alk is C1-6alkanediyl; R1 is hydrogen, C1-6alkyl, aryl or aryl C1-6alkyl; R2, R3 and R4 are each independently selected from hydrogen, halo, hydroxy, nitro, cyano, C1-6alkyl, C1-6alkyloxy, trifluoromethyl, C1-6alkylthio, mercapto, amino, mono- and di(C1-6alkyl)amino, carboxyl, C1-6alkyloxycarbonyl or C1-6alkylcarbonyl; R5 is hydrogen, C1-6alkyl, phenyl or phenylC1-6alkyl; R6 is hydrogen, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, or a radical of formula -NR8R9, wherein R8 and R9 are each independently selected from hydrogen, C1-6alkyl, phenyl or phenylC1-6alkyl; R7 is hydrogen or C1-6alkyl; or R6 and R7 taken together may form a bivalent radical of formula -R6-R7-; having central dopamine and serotonin antogonistic activity; their preparation, compositions containing them and their use as a medicine.</p> |